{'fraction_non_alphanumeric': 0.04234527687296417, 'fraction_numerical': 0.00760043431053203, 'mean_word_length': 6.147286821705427, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Second generation anti‐cyclic citrullinated peptide (anti‐CCP2) antibodies can replace other anti‐filaggrin antibodies and improve rheumatoid arthritis diagnosis

We compared the diagnostic performance of anti‐cyclic citrullinated peptide antibodies detected with second‐generation enzyme immunoassay (anti‐CCP2) with that of IgM‐rheumatoid factor (RF), anti‐perinuclear factor (APF), and anti‐keratin antibodies (AKA). The sensitivity of anti‐CCP2 was better than that of APF and AKA: they were detected in 25% rheumatoid arthritis (RA) patients without detectable APF or AKA. Their specificity, evaluated in other inflammatory rheumatic disease, was similar to that of APF and AKA. Despite the lower specificity, IgM‐RF in combination with anti‐CCP2 is interesting, as they do not completely overlap. Anti‐CCP2 antibody detection seems to be a good alternative to other anti‐filaggrin antibodies in the diagnosis of RA.